Position in NVS
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$1,513,601
+$479,484 QoQ
Shares Held
9,658
+42.7% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#504
of 1,603 holders
Holding Since
Mar 2020
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026AlphaCore Capital LLC holds $65,400,986 across 13 Drug Manufacturers - General names. NVS ranks #9 (2.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
13,692 | $16,422,596 | |
| 2 | JNJ |
Johnson & Johnson
|
50,226 | $12,755,897 | |
| 3 | ABBV |
AbbVie Inc.
|
45,476 | $11,443,580 | |
| 4 | MRK |
Merck & Co., Inc.
|
51,249 | $6,585,496 | |
| 5 | PFE |
Pfizer Inc
|
208,486 | $5,020,342 | |
| 6 | AMGN |
Amgen Inc
|
13,140 | $4,758,256 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
46,389 | $2,672,934 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
16,707 | $2,110,762 |
All Filings in NVS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,513,601 | 9,658 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $1,034,117 | 6,770 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,010,391 | 21,835 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $2,944,903 | 22,964 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $935,286 | 7,729 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $523,956 | 4,700 | Shares | Sole | 2025-05-12 | |
| 2020-03-31 | $4,534 | 55 | Shares | Sole | 2020-05-04 | |
| No filing history on record for this holder in this stock. | ||||||